[go: up one dir, main page]

CL2018001051A1 - Vacunas de ácido nucleico contra el virus varicela zoster (vzv) - Google Patents

Vacunas de ácido nucleico contra el virus varicela zoster (vzv)

Info

Publication number
CL2018001051A1
CL2018001051A1 CL2018001051A CL2018001051A CL2018001051A1 CL 2018001051 A1 CL2018001051 A1 CL 2018001051A1 CL 2018001051 A CL2018001051 A CL 2018001051A CL 2018001051 A CL2018001051 A CL 2018001051A CL 2018001051 A1 CL2018001051 A1 CL 2018001051A1
Authority
CL
Chile
Prior art keywords
vzv
nucleic acid
zoster virus
vaccines against
varicella zoster
Prior art date
Application number
CL2018001051A
Other languages
English (en)
Inventor
Giuseppe Ciaramella
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of CL2018001051A1 publication Critical patent/CL2018001051A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16771—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LOS ASPECTOS DE LA DESCRIPCIÓN HACEN REFERENCIA A VACUNAS DE ÁCIDOS NUCLEICOS. LAS VACUNAS INCLUYEN AL MENOS UN POLINUCLEÓTIDO DE ARN QUE TIENE UN MARCO DE LECTURA ABIERTO CODIFICANTE DE AL MENOS UN ANTÍGENO DEL VIRUS VARICELA-ZÓSTER (VZV). ASIMISMO SE DESCRIBEN MÉTODOS DE PREPARACIÓN Y USO DE TALES VACUNAS.
CL2018001051A 2015-10-22 2018-04-20 Vacunas de ácido nucleico contra el virus varicela zoster (vzv) CL2018001051A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562245234P 2015-10-22 2015-10-22
US201562245031P 2015-10-22 2015-10-22
US201562247697P 2015-10-28 2015-10-28
US201662335348P 2016-05-12 2016-05-12

Publications (1)

Publication Number Publication Date
CL2018001051A1 true CL2018001051A1 (es) 2018-10-19

Family

ID=58558195

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001051A CL2018001051A1 (es) 2015-10-22 2018-04-20 Vacunas de ácido nucleico contra el virus varicela zoster (vzv)

Country Status (20)

Country Link
US (4) US11643441B1 (es)
EP (1) EP3364980A4 (es)
JP (4) JP6925688B2 (es)
KR (1) KR20180094859A (es)
CN (2) CN117731769A (es)
AU (2) AU2016342371B2 (es)
BR (1) BR112018008051A2 (es)
CA (1) CA3002912A1 (es)
CL (1) CL2018001051A1 (es)
CO (1) CO2018005265A2 (es)
EA (1) EA201891001A1 (es)
IL (1) IL258827A (es)
MA (1) MA46080A (es)
MX (1) MX2018004915A (es)
PE (1) PE20181529A1 (es)
PH (1) PH12018500858A1 (es)
SG (1) SG11201803360UA (es)
TN (1) TN2018000152A1 (es)
TW (1) TW201729838A (es)
WO (1) WO2017070601A1 (es)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP4218805A1 (en) 2015-07-21 2023-08-02 ModernaTX, Inc. Infectious disease vaccines
US12150980B2 (en) 2015-07-30 2024-11-26 Modernatx, Inc. Concatemeric peptide epitope RNAs
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
TW201729838A (zh) 2015-10-22 2017-09-01 現代公司 用於水痘帶狀疱疹病毒 (vzv)之核酸疫苗
PT3718565T (pt) 2015-10-22 2022-07-20 Modernatx Inc Vacinas contra vírus respiratórios
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
EP3364982A4 (en) 2015-10-22 2019-04-17 ModernaTX, Inc. VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
EP3458107B1 (en) 2016-05-18 2024-03-13 ModernaTX, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
CN115837014A (zh) 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
CN109937253B (zh) 2016-09-14 2023-06-30 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
WO2018187590A1 (en) 2017-04-05 2018-10-11 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
US20210187098A1 (en) * 2017-04-28 2021-06-24 Glaxosmithkline Biologicals Sa Vaccination
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
US11866696B2 (en) 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
EP3668971B8 (en) 2017-08-18 2024-05-29 ModernaTX, Inc. Rna polymerase variants
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
JP2021504445A (ja) * 2017-11-21 2021-02-15 モデルナティーエックス， インコーポレイテッド エプスタイン−バーウイルスワクチン
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
MA53652A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg de haute pureté et leurs utilisations
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
CN109602901B (zh) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
AU2020224103A1 (en) 2019-02-20 2021-09-16 Modernatx, Inc. Rna polymerase variants for co-transcriptional capping
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
KR20210149727A (ko) 2019-03-11 2021-12-09 모더나티엑스, 인크. 유가식(fed-batch) 시험관내 전사 공정
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
CN112138153B (zh) 2019-06-28 2022-08-23 怡道生物科技(苏州)有限公司 一种重组带状疱疹疫苗组合物及其用途
CN112142829B (zh) * 2019-06-28 2022-02-22 怡道生物科技(苏州)有限公司 水痘-带状疱疹病毒gE蛋白突变体及其表达方法
CN112870344B (zh) * 2019-11-29 2022-07-19 北京绿竹生物技术股份有限公司 一种重组水痘带状疱疹病毒疫苗
CN113045670B (zh) * 2019-12-27 2022-11-01 华南农业大学 一种可溶性鸡α干扰素融合蛋白及其生产方法与应用
CN113521268A (zh) 2020-04-22 2021-10-22 生物技术Rna制药有限公司 冠状病毒疫苗
CN111840538A (zh) * 2020-05-29 2020-10-30 中山大学 一种水痘-带状疱疹病毒亚单位纳米疫苗的制备方法和应用
JP2023533721A (ja) 2020-07-02 2023-08-04 ライフ テクノロジーズ コーポレーション トリヌクレオチドキャップ類似体、それらの調製、及び使用
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
EP4212173A4 (en) * 2020-09-11 2024-10-23 Eubiologics Co., Ltd. Vaccine composition for chickenpox or varicella zoster and method of using same
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
CN112386688B (zh) * 2021-01-20 2021-09-24 广东新征程生命科学有限公司 一种用于病毒治疗的含有免疫细胞的药物组合物
CN113144186B (zh) * 2021-02-09 2023-09-29 中国医学科学院医学生物学研究所 一种水痘-带状疱疹疫苗组合物及其制备方法和应用
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
CN113372453B (zh) * 2021-06-11 2022-03-04 湖南兀邦生物科技有限公司 一种融合蛋白及猪流行性腹泻病毒s1蛋白重组亚单位疫苗
CA3230031A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids
WO2023056912A1 (en) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for vzv
TW202327646A (zh) * 2021-10-15 2023-07-16 美商輝瑞大藥廠 Rna分子
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
CN114081943B (zh) * 2021-11-08 2024-04-02 中国医学科学院医学生物学研究所 一种水痘-带状疱疹mRNA疫苗组合物及其制备方法和应用
CN114113594B (zh) * 2021-11-23 2024-06-21 上海凯创生物技术有限公司 一种抗原稀释液、以及免疫缺陷病毒的检测试剂盒
JP2024541466A (ja) 2021-11-24 2024-11-08 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 水痘帯状疱疹ウイルス免疫原組成物及びその使用
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
EP4470543A1 (en) * 2022-01-25 2024-12-04 Kawasaki Institute of Industrial Promotion Rna-containing composition for transdermal administration, and method for administering said composition
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
CN118871587A (zh) * 2022-03-21 2024-10-29 厦门大学 截短的水痘-带状疱疹病毒囊膜糖蛋白gE
CA3248209A1 (en) 2022-05-25 2023-11-30 CureVac SE Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH)
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
CN117660494A (zh) * 2022-09-07 2024-03-08 远大赛威信生命科学(南京)有限公司 用于表达水痘-带状疱疹病毒抗原蛋白的mRNA及其用途
DE202023106198U1 (de) 2022-10-28 2024-03-21 CureVac SE Impfstoff auf Nukleinsäurebasis
EP4615498A1 (en) * 2022-11-08 2025-09-17 Vernagen, LLC Engineered varicella zoster virus shingles mrna vaccine
CN116474086A (zh) * 2022-11-24 2023-07-25 中国药科大学 一种预防和/或治疗带状疱疹病的疫苗试剂
CN116023510B (zh) * 2022-12-01 2023-09-22 北京吉诺卫生物科技有限公司 双佐剂重组带状疱疹疫苗
WO2024154052A1 (en) * 2023-01-16 2024-07-25 Pfizer Inc. Immunogenic compositions and methods of inducing an immune response against varicella zoster virus
EP4653469A1 (en) * 2023-01-19 2025-11-26 Xiamen University Fusion protein of ge and gi of varicella-zoster virus and use
TW202444745A (zh) * 2023-01-24 2024-11-16 加拿大商普羅維登斯醫療控股公司 用於治療疾病的組合物和方法
CN116355917B (zh) * 2023-02-15 2023-12-01 上海臻上医药科技有限公司 一种水痘-带状疱疹病毒mRNA疫苗及其应用
CN116655748B (zh) * 2023-02-28 2024-07-26 易慧生物技术(上海)有限公司 一种截短型水痘-带状疱疹病毒gE蛋白及其应用
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2025002352A1 (zh) * 2023-06-28 2025-01-02 上海瑞宏迪医药有限公司 一种含有阳离子脂质的药物组合物及其用途
WO2025002359A1 (zh) * 2023-06-30 2025-01-02 深圳深信生物科技有限公司 水痘带状疱疹病毒(vzv)疫苗
WO2025034612A1 (en) * 2023-08-04 2025-02-13 Modernatx, Inc. Varicella-zoster virus mrna vaccine
CN119592585A (zh) * 2023-09-11 2025-03-11 深圳瑞吉生物科技有限公司 水痘-带状疱疹病毒mRNA疫苗及其应用
CN119746053A (zh) * 2023-09-28 2025-04-04 珠海丽凡达生物技术有限公司 水痘带状疱疹病毒疫苗及其制备方法和应用
CN119746054A (zh) * 2023-09-28 2025-04-04 珠海丽凡达生物技术有限公司 水痘带状疱疹病毒疫苗及其制备方法和应用
CN119587687A (zh) * 2023-09-28 2025-03-11 珠海丽凡达生物技术有限公司 水痘带状疱疹病毒疫苗及其制备方法和应用
CN120020142A (zh) * 2023-11-20 2025-05-20 上海蓝鹊生物医药有限公司 一种vzv抗原变体、核酸、药物组合物及其应用
CN118240844B (zh) * 2024-05-27 2024-12-13 北京悦康科创医药科技股份有限公司 带状疱疹mRNA疫苗及其制备方法和应用

Family Cites Families (257)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
FR2676072B1 (fr) 1991-05-03 1994-11-18 Transgene Sa Vecteur de delivrance d'arn.
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6251665B1 (en) 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
CA2305785A1 (en) 1997-10-07 1999-04-15 University Of Maryland Biotechnology Institute Method for introducing and expressing rna in animal cells
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
WO2000050006A2 (en) 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
EP1818409A1 (en) 1999-09-09 2007-08-15 CureVac GmbH Transfer of mRNAusing polycationic compounds
WO2001021810A1 (en) 1999-09-17 2001-03-29 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US7060291B1 (en) 1999-11-24 2006-06-13 Transave, Inc. Modular targeted liposomal delivery system
BR0112637A (pt) 2000-07-21 2003-06-10 Glaxo Group Ltd Sequências do vìrus do papiloma códon-otimizadas
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7708915B2 (en) 2004-05-06 2010-05-04 Castor Trevor P Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
DE50211110D1 (de) 2001-04-21 2007-12-06 Curevac Gmbh INJEKTIONSGERÄT FÜR mRNA APPLIKATION
DE50214201D1 (de) 2001-06-05 2010-03-25 Curevac Gmbh Stabilisierte mRNA mit erhöhtem G/C-Gehalt, enkodierend für ein bakterielles Antigen sowie deren Verwendung
AU2002319668A1 (en) 2001-07-27 2003-02-17 President And Fellows Of Harvard College Laminar mixing apparatus and methods
WO2003028657A2 (en) 2001-10-03 2003-04-10 The Johns Hopkins University Compositions for oral gene therapy and methods of using same
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
NZ573064A (en) 2002-04-04 2011-02-25 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
WO2003092665A2 (en) 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
US7410795B2 (en) 2002-12-23 2008-08-12 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US7419674B2 (en) 2003-07-11 2008-09-02 Alpha Vax, Inc. Alpha virus-based cytomegalovirus vaccines
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US8957034B2 (en) 2004-01-28 2015-02-17 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
WO2006097793A2 (en) 2004-04-15 2006-09-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
EP1856179B1 (en) 2004-12-10 2013-05-15 Kala Pharmaceuticals, Inc. Functionalized poly (ether-anhydride) block copolymers
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
CA2603853C (en) 2005-04-01 2013-11-19 Intezyne Technologies, Incorporated Polymeric micelles for drug delivery
US8273339B2 (en) 2005-04-12 2012-09-25 Nektar Therapeutics Polymer-based compositions and conjugates of antimicrobial agents
RS53968B1 (sr) 2005-06-16 2015-08-31 Nektar Therapeutics Konjugati koji imaju spojnicu koja može da se razgradi i polimerni reagensi koji su korisni za pripremu takvih konjugata
EP4174179B1 (en) 2005-08-23 2025-05-07 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
DE102006007433A1 (de) 2006-02-17 2007-08-23 Curevac Gmbh Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
CA2642905C (en) 2006-02-21 2015-04-28 Nektar Therapeutics Al, Corporation Segmented degradable polymers and conjugates made therefrom
EP2019691B1 (en) 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymers for functional particles
EP2046954A2 (en) 2006-07-31 2009-04-15 Curevac GmbH NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
ES2360538T3 (es) 2006-09-08 2011-06-06 Johns Hopkins University Composiciones para aumentar el transporte a través de moco.
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
AU2007339280B2 (en) 2006-12-21 2013-12-05 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US20100330122A1 (en) * 2007-07-19 2010-12-30 Gale Smith VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES (VLPs) AND ANTIGENS
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
EP2644594B1 (en) 2007-09-28 2017-08-23 Pfizer Inc Cancer Cell Targeting Using Nanoparticles
EP3424525A1 (en) 2007-10-12 2019-01-09 Massachusetts Institute Of Technology Vaccine nanotechnology
NZ588583A (en) 2008-04-15 2012-08-31 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
PL2285350T3 (pl) 2008-06-16 2018-03-30 Pfizer Inc. Sposoby otrzymywania funkcjonalizowanych kopolimerów dwublokowych stanowiących środki kierujące do stosowania przy wytwarzaniu nanocząstek terapeutycznych
WO2010005723A2 (en) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
ES2721850T3 (es) 2008-06-16 2019-08-05 Pfizer Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas
US20100087337A1 (en) 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP3225621A1 (en) 2008-10-09 2017-10-04 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
MX351819B (es) 2008-11-10 2017-10-30 Alnylam Pharmaceuticals Inc Lipidos y composiciones novedosas para el suministro de terapeuticos.
WO2010057203A2 (en) 2008-11-17 2010-05-20 The Board Of Regents Of The University Of Texas System Hdl particles for delivery of nucleic acids
EP2379064B1 (en) 2008-12-15 2020-02-26 Pfizer Inc. Long circulating nanoparticles for sustained release of therapeutic agents
WO2010088927A1 (en) 2009-02-09 2010-08-12 Curevac Gmbh Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
JP5622254B2 (ja) 2009-03-31 2014-11-12 国立大学法人東京大学 二本鎖リボ核酸ポリイオンコンプレックス
RU2600798C2 (ru) 2009-04-01 2016-10-27 Юниверсити Оф Майами Композиции вакцин и способы их применения
WO2010127159A2 (en) 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Polymeric micelles for polynucleotide encapsulation
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
RU2573409C2 (ru) 2009-11-04 2016-01-20 Дзе Юниверсити Оф Бритиш Коламбиа Содержащие нуклеиновые кислоты липидные частицы и относящиеся к ним способы
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
EA201290498A1 (ru) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
JP6175237B2 (ja) 2009-12-15 2017-08-02 ファイザー・インク コルチコステロイドを含む治療用ポリマーナノ粒およびそれを製造かつ使用する方法
JP5965844B2 (ja) 2009-12-15 2016-08-10 バインド セラピューティックス インコーポレイテッド 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物
ES2536429T3 (es) 2010-01-24 2015-05-25 Novartis Ag Micropartículas de polímero biodegradables irradiadas
WO2011119262A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
US20110262491A1 (en) 2010-04-12 2011-10-27 Selecta Biosciences, Inc. Emulsions and methods of making nanocarriers
EP2387999A1 (en) 2010-05-21 2011-11-23 CureVac GmbH Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
JP2013531634A (ja) 2010-05-24 2013-08-08 メルク・シャープ・エンド・ドーム・コーポレイション オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
US20130196948A1 (en) 2010-06-25 2013-08-01 Massachusetts Insitute Of Technology Polymers for biomaterials and therapeutics
CA2804492A1 (en) 2010-07-06 2012-01-12 Novartis Ag Immunisation of large mammals with low doses of rna
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
CN108042799A (zh) 2010-07-06 2018-05-18 诺华股份有限公司 阳离子水包油乳液
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
CN103052400B (zh) * 2010-07-06 2016-11-16 诺华股份有限公司 自我复制rna分子的病毒样递送颗粒
JP5948327B2 (ja) 2010-07-30 2016-07-06 キュアヴァック アーゲー トランスフェクションおよび免疫刺激のためのジスルフィド架橋されたカチオン性成分との核酸の複合体形成
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
US20120058153A1 (en) 2010-08-20 2012-03-08 Selecta Biosciences, Inc. Synthetic nanocarrier vaccines comprising proteins obtained or derived from human influenza a virus hemagglutinin
PT4008357T (pt) 2010-08-31 2023-01-11 Glaxosmithkline Biologicals Sa Lipossomas pequenos para entrega de arn que codifica um imunogénio
TR201908635T4 (tr) 2010-08-31 2019-07-22 Glaxosmithkline Biologicals Sa Protein kodlayıcı rna?nın lipozomal verilmesine uygun lipitler.
EP4226941B1 (en) 2010-08-31 2024-10-23 GlaxoSmithKline Biologicals SA Pegylated liposomes for delivery of immunogen-encoding rna
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
KR102162111B1 (ko) * 2010-10-11 2020-10-07 노파르티스 아게 항원 전달 플랫폼
WO2012054923A2 (en) 2010-10-22 2012-04-26 Bind Biosciences, Inc. Therapeutic nanoparticles with high molecular weight copolymers
CA3054532C (en) 2010-11-05 2022-07-12 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
US20120189700A1 (en) 2011-01-19 2012-07-26 Zoraida Aguilar Nanoparticle Based Immunological Stimulation
KR20140007404A (ko) * 2011-01-31 2014-01-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 신규 허피스 항원을 암호화하는 핵산 분자, 이것을 포함하는 백신 및 이것의 사용 방법
US20140066363A1 (en) 2011-02-07 2014-03-06 Arun K. Bhunia Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
US9901554B2 (en) 2011-03-31 2018-02-27 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
CA2831471C (en) 2011-03-31 2020-02-25 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
BR112013029490A2 (pt) 2011-05-17 2019-09-24 Moderna Therapeutics Inc ácidos nucleicos projetados e métodos de uso dos mesmos para vertebrados não humanos
WO2012166923A2 (en) 2011-05-31 2012-12-06 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
CN103857387B (zh) 2011-06-02 2017-03-15 加利福尼亚大学董事会 膜包封的纳米颗粒及使用方法
EP3332802A1 (en) 2011-07-06 2018-06-13 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
JP2014520807A (ja) 2011-07-06 2014-08-25 ノバルティス アーゲー 免疫原性組成物およびその使用
ES2861428T3 (es) 2011-07-06 2021-10-06 Glaxosmithkline Biologicals Sa Liposomas que presentan una relación N:P útil para suministro de moléculas de ARN
CN103796639B (zh) 2011-07-06 2017-05-31 诺华股份有限公司 阳离子水包油乳液
ES2670944T3 (es) 2011-07-21 2018-06-04 Croda International Plc Copolímeros de bloques de poliéter-poliamida ramificados y métodos de preparación y uso de los mismos
JP2014531476A (ja) 2011-08-26 2014-11-27 アローヘッド リサーチ コーポレイション インビボ核酸送達のためのポリ（ビニルエステル）ポリマー
CA2845845A1 (en) 2011-08-31 2013-03-07 Mallinckrodt Llc Nanoparticle peg modification with h-phosphonates
CN103930547A (zh) 2011-09-02 2014-07-16 诺华股份有限公司 用于治疗hsf1相关疾病的有机组合物
EP3384938A1 (en) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2747761A1 (en) 2011-09-22 2014-07-02 Bind Therapeutics, Inc. Methods of treating cancers with therapeutic nanoparticles
US9375388B2 (en) 2011-09-23 2016-06-28 Indian Institute Of Technology, Bombay Nanoparticle based cosmetic composition
MX2014004214A (es) 2011-10-11 2014-05-07 Novartis Ag Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes.
BR112014008932A2 (pt) 2011-10-14 2019-09-24 Sandia Corp bicamadas lipídicas suportadas em nanopartículas porosas (protocélulas) para administração direcionada, incluindo a administração transdérmica de uma carga e métodos associados
HUE057604T2 (hu) 2011-10-18 2022-06-28 Dicerna Pharmaceuticals Inc Amin-kationos lipidek és felhasználásuk
CN113149869A (zh) 2011-10-27 2021-07-23 麻省理工学院 能够形成药物包封微球的在n末端上官能化的氨基酸衍生物
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
WO2013130161A1 (en) 2011-12-14 2013-09-06 modeRNA Therapeutics Methods of responding to a biothreat
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US20130165504A1 (en) 2011-12-21 2013-06-27 modeRNA Therapeutics Methods of increasing the viability or longevity of an organ or organ explant
CA2863632C (en) 2012-01-19 2017-07-11 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
AU2013214799B2 (en) 2012-02-03 2016-05-12 Rutgers, The State Of University Of New Jersey Polymeric biomaterials derived from phenolic monomers and their medical uses
CN104105750A (zh) 2012-02-10 2014-10-15 纳幕尔杜邦公司 高-x两嵌段共聚物的制备、纯化和使用
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
JP2015516143A (ja) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
ES2719598T3 (es) 2012-05-25 2019-07-11 Curevac Ag Inmovilización reversible y/o liberación controlada de ácidos nucleicos contenidos en nanopartículas mediante revestimientos poliméricos (biodegradables)
AU2013271392B2 (en) 2012-06-08 2018-02-15 Ethris Gmbh Pulmonary delivery of mRNA to non-lung target cells
EP2885419A4 (en) 2012-08-14 2016-05-25 Moderna Therapeutics Inc ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
US20150307542A1 (en) 2012-10-03 2015-10-29 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
ES2676470T3 (es) 2012-11-09 2018-07-19 Biontech Rna Pharmaceuticals Gmbh Método para la expresión de ARN en células
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
US20150366997A1 (en) * 2012-12-07 2015-12-24 Shire Human Genetics Therapies, Inc. COMPOSITIONS AND METHODS FOR mRNA DELIVERY
US9687448B2 (en) 2012-12-07 2017-06-27 Alnylam Pharmaceuticals, Inc. Nucleic acid lipid particle formulations
EP2931914A4 (en) 2012-12-13 2016-08-17 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR CHANGING THE CELL PHENOTYPE
SG11201506052PA (en) 2013-02-22 2015-09-29 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
AU2014224205C1 (en) * 2013-03-08 2019-04-04 Novartis Ag Lipids and lipid compositions for the delivery of active agents
PT2970456T (pt) 2013-03-14 2021-08-06 Translate Bio Inc Métodos e composições para a administração de anticorpos codificados por marn
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US20160032316A1 (en) 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
SMT201800264T1 (it) 2013-03-15 2018-07-17 Translate Bio Inc Potenziamento sinergico del rilascio di acidi nucleici attraverso formulazioni miscelate
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
US20160017313A1 (en) 2013-03-15 2016-01-21 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
US20160032273A1 (en) 2013-03-15 2016-02-04 Moderna Therapeutics, Inc. Characterization of mrna molecules
TW201534578A (zh) 2013-07-08 2015-09-16 Daiichi Sankyo Co Ltd 新穎脂質
EP3024483B1 (en) 2013-07-25 2020-01-15 Calder Biosciences Inc. Conformationally stabilized rsv pre-fusion f proteins
CA2915728A1 (en) 2013-08-21 2015-02-26 Thomas Kramps Respiratory syncytial virus (rsv) vaccine
SG10201801428RA (en) 2013-08-21 2018-03-28 Curevac Ag Method for increasing expression of rna-encoded proteins
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
EP3058082A4 (en) 2013-10-18 2017-04-26 ModernaTX, Inc. Compositions and methods for tolerizing cellular systems
WO2015130584A2 (en) * 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
EP3154576A1 (en) 2014-06-13 2017-04-19 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
EP3157573A4 (en) 2014-06-19 2018-02-21 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US20170202979A1 (en) 2014-07-17 2017-07-20 Modernatx, Inc. Terminal modifications of polynucleotides
EP3233118A1 (en) * 2014-12-18 2017-10-25 GlaxoSmithKline Biologicals S.A. Vaccination
US20180000953A1 (en) 2015-01-21 2018-01-04 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016164762A1 (en) 2015-04-08 2016-10-13 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
AU2016253972B2 (en) 2015-04-27 2020-01-02 Acuitas Therapeutics Inc. Nucleoside-modified RNA for inducing an adaptive immune response
EP3307305A4 (en) 2015-06-10 2019-05-22 Modernatx, Inc. TARGETED ADAPTIVE VACCINES
EP3310384A1 (en) 2015-06-17 2018-04-25 CureVac AG Vaccine composition
WO2017015457A1 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Ebola vaccine
EP4218805A1 (en) 2015-07-21 2023-08-02 ModernaTX, Inc. Infectious disease vaccines
US12150980B2 (en) 2015-07-30 2024-11-26 Modernatx, Inc. Concatemeric peptide epitope RNAs
WO2017019935A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Multimeric mrna
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
US20180237849A1 (en) 2015-08-17 2018-08-23 Modernatx, Inc. Rna mapping/fingerprinting
DK3350157T3 (da) 2015-09-17 2022-02-14 Modernatx Inc Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler
JP6990176B2 (ja) 2015-10-05 2022-02-03 モデルナティエックス インコーポレイテッド メッセンジャーリボ核酸薬物の治療投与のための方法
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
CA3003090A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Cancer vaccines
PT3718565T (pt) 2015-10-22 2022-07-20 Modernatx Inc Vacinas contra vírus respiratórios
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
EP3364982A4 (en) 2015-10-22 2019-04-17 ModernaTX, Inc. VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES
JP7384512B2 (ja) 2015-10-22 2023-11-21 モデルナティエックス インコーポレイテッド 広域インフルエンザウイルスワクチン
TW201729838A (zh) 2015-10-22 2017-09-01 現代公司 用於水痘帶狀疱疹病毒 (vzv)之核酸疫苗
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
SG11201803365RA (en) 2015-10-22 2018-05-30 Modernatx Inc Herpes simplex virus vaccine
JP7687767B2 (ja) 2015-10-22 2025-06-03 モデルナティエックス インコーポレイテッド 呼吸器合胞体ウイルスワクチン
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
AU2016369612B2 (en) 2015-12-17 2023-06-01 Modernatx, Inc. Polynucleotides encoding methylmalonyl-CoA mutase
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
US12123030B2 (en) 2016-05-18 2024-10-22 Modernatx, Inc. Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia
WO2017201317A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polyribonucleotides containing reduced uracil content and uses thereof
MA45037A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polythérapie à base d'arnm pour le traitement du cancer
WO2017201347A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
MY201498A (en) 2016-05-18 2024-02-27 Modernatx Inc Polynucleotides encoding citrin for the treatment of citrullinemia type 2
EP3458590B9 (en) 2016-05-18 2021-08-18 ModernaTX, Inc. Polynucleotides encoding -galactosidase a for the treatment of fabry disease
EP3458107B1 (en) 2016-05-18 2024-03-13 ModernaTX, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
ES2973443T3 (es) 2016-05-18 2024-06-20 Modernatx Inc Polinucleótidos que codifican galactosa-1-fosfato uridililtransferasa para el tratamiento de galactosemia de tipo 1
US20190298657A1 (en) 2016-05-18 2019-10-03 Modernatx, Inc. Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
US20200085916A1 (en) 2016-05-18 2020-03-19 Modernatx, Inc. Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
CN115837014A (zh) 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
CA3027201A1 (en) 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CN109937253B (zh) 2016-09-14 2023-06-30 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
KR20190086681A (ko) 2016-10-26 2019-07-23 모더나티엑스, 인크. 면역 반응을 향상시키기 위한 메신저 리보핵산 및 그의 사용 방법
MX2019004913A (es) 2016-10-26 2019-09-16 Curevac Ag Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
EP3532613A4 (en) 2016-10-26 2020-05-06 ModernaTX, Inc. METHOD AND COMPOSITIONS FOR RNA MAPPING
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
US20180243225A1 (en) 2017-01-25 2018-08-30 Modernatx, Inc. Ebola/marburg vaccines
WO2018144082A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Rna cancer vaccines
MX2019009070A (es) 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
EP3577221A4 (en) 2017-02-01 2020-12-23 ModernaTX, Inc. Polynucleotide secondary structure
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
WO2018157009A1 (en) 2017-02-24 2018-08-30 Modernatx, Inc. Nucleic acid-based therapy of muscular dystrophies
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
RS63953B1 (sr) 2017-03-15 2023-02-28 Modernatx Inc Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
US20200038499A1 (en) 2017-03-22 2020-02-06 Modernatx, Inc. Rna bacterial vaccines
WO2018187590A1 (en) 2017-04-05 2018-10-11 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
MA49463A (fr) 2017-04-26 2021-05-05 Modernatx Inc Vaccin contre le virus de l'herpès simplex
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
WO2018232355A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna antibodies
EP3668971B8 (en) 2017-08-18 2024-05-29 ModernaTX, Inc. Rna polymerase variants
WO2019036670A2 (en) 2017-08-18 2019-02-21 Modernatx, Inc. EFFECTIVE MRNA VACCINES
US11866696B2 (en) 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
US20190192646A1 (en) 2017-11-03 2019-06-27 Modernatx, Inc. Salmonella vaccines
JP2021504445A (ja) 2017-11-21 2021-02-15 モデルナティーエックス， インコーポレイテッド エプスタイン−バーウイルスワクチン
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
AU2019293244A1 (en) 2018-06-27 2021-02-11 Modernatx, Inc. Personalized cancer vaccine epitope selection
EP3863645A4 (en) 2018-09-13 2022-11-16 ModernaTX, Inc. MODIFIED mRNA FOR THE TREATMENT OF FAMILY PROGRESSIVE INTRAHEPATIC CHOLESTASIS DISORDERS
MA53652A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg de haute pureté et leurs utilisations
JP7410135B2 (ja) 2018-09-19 2024-01-09 モデルナティエックス インコーポレイテッド 治療薬の細胞内送達のための化合物及び組成物
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
AU2019374818A1 (en) 2018-11-07 2021-05-27 Modernatx, Inc. RNA cancer vaccines
AU2020224103A1 (en) 2019-02-20 2021-09-16 Modernatx, Inc. Rna polymerase variants for co-transcriptional capping
KR20210149727A (ko) 2019-03-11 2021-12-09 모더나티엑스, 인크. 유가식(fed-batch) 시험관내 전사 공정
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
CA3142352A1 (en) 2019-05-31 2020-12-03 Modernatx, Inc. Expanded t cell assay
EP4013865A4 (en) 2019-08-14 2023-08-23 ModernaTX, Inc. PROCEDURE FOR PURIFICATION OF DOWNSTREAM PRODUCTS OF IN VITRO TRANSCRIPTION
JP2022547313A (ja) 2019-09-11 2022-11-11 モデルナティエックス インコーポレイテッド ヒトサイトメガロウイルスワクチン
AU2020348860A1 (en) 2019-09-19 2022-04-07 Modernatx, Inc. Cap guides and methods of use thereof for RNA mapping

Also Published As

Publication number Publication date
AU2016342371A1 (en) 2018-06-07
PH12018500858A1 (en) 2018-10-29
JP2018536022A (ja) 2018-12-06
BR112018008051A2 (pt) 2018-11-13
EP3364980A4 (en) 2019-07-10
US20230374079A1 (en) 2023-11-23
MA46080A (fr) 2019-07-10
SG11201803360UA (en) 2018-05-30
JP2023116608A (ja) 2023-08-22
MX2018004915A (es) 2019-04-01
JP6925688B2 (ja) 2021-08-25
AU2016342371B2 (en) 2023-05-11
US11643441B1 (en) 2023-05-09
US20250188132A1 (en) 2025-06-12
EP3364980A1 (en) 2018-08-29
CO2018005265A2 (es) 2018-11-22
JP2021121630A (ja) 2021-08-26
EA201891001A1 (ru) 2018-11-30
US20230303632A1 (en) 2023-09-28
TN2018000152A1 (en) 2019-10-04
CN117731769A (zh) 2024-03-22
PE20181529A1 (es) 2018-09-26
WO2017070601A1 (en) 2017-04-27
CN108472309A (zh) 2018-08-31
KR20180094859A (ko) 2018-08-24
AU2023202500A1 (en) 2023-05-18
JP7330590B2 (ja) 2023-08-22
JP2025016615A (ja) 2025-02-04
IL258827A (en) 2018-06-28
CA3002912A1 (en) 2017-04-27
TW201729838A (zh) 2017-09-01

Similar Documents

Publication Publication Date Title
CL2018001051A1 (es) Vacunas de ácido nucleico contra el virus varicela zoster (vzv)
AR132094A2 (es) Composiciones detergentes, variantes de lipasa y polinucleótidos que las codifican
BR112018008090A2 (pt) vacina de vírus do herpes simplex.
CO2019006541A2 (es) Administración viral de neoantígenos
CO2019013609A2 (es) Vectores de neoantígeno de alfavirus
MX382518B (es) Antigenos de citomegalovirus y su uso.
MX384795B (es) Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso.
CO2017011238A2 (es) Anticuerpos anti-c1s humanizados
MX373660B (es) Fibroblastos de embrion de pollo inmortalizados.
MX383596B (es) Moleculas biespecificas que son inmunorreactivas con celulas efectoras inmunes que expresan un receptor activador y un antigeno expresado por una celula infectada por un virus y usos de las mismas.
BR112018007017A2 (pt) polipeptídeos
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
MX383507B (es) Antígenos del virus de la inmunodeficiencia humana, vectores, composiciones y métodos de uso de estos.
MX2021010060A (es) Produccion de virus en huevos aviares.
JO3765B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18 (18hpv)
BR112017016897A2 (pt) cepas fúngicas e métodos de uso
MX379312B (es) Anticuerpos especificos para fcrn.
MX387400B (es) Células de mamífero que expresan antígenos de citomegalovirus.
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
MA40518A (fr) Matrices polymères émissives
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
MX381872B (es) Mutantes de neumolisina y metodos de uso de los mismos.
MY181007A (en) Scale drop disease (sdd) causative virus and derivatives thereof
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
AR105431A1 (es) Vacunas para enfermedades infecciosas